ArticleFrontiers in oncology2025
The effectiveness of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in predicting lymph node metastasis in radiologically n0 locally advanced upper rectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HALP score outperforms systemic inflammatory biomarkers for prognosis in locally advanced rectal cancer.Biomolecules & biomedicine · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Reliable preoperative identification of lymph node metastasis in clinically node-negative (cN0) patients with locally advanced upper rectal cancer (LAURC) remains a major clinical challenge due to the limited sensitivity of imaging modalities. The HALP score-calculated from hemoglobin, albumin, lymphocyte, and platelet counts-has emerged as a promising marker reflecting systemic inflammation and nutritional status. This study aimed to investigate the association between preoperative HALP scores and histopathologically confirmed lymph node metastasis in cN0 LAURC patients and to assess its diagnostic performance. Methods: This retrospective study included 62 patients who underwent curative resection for cN0 LAURC between January 2020 and December 2023. HALP scores were computed using the formula: hemoglobin (g/L) × albumin (g/L) × lymphocyte count (/L) ÷ platelet count (/L), based on fasting blood samples collected within one week prior to surgery. Patients were stratified according to the presence or absence of pathological lymph node metastasis. ROC curve analysis was used to determine the optimal HALP cut-off value. Strict exclusion criteria were applied to minimize confounding from comorbidities affecting hematologic parameters. Results: Lymph node metastasis was confirmed in 21 patients (33.9%). Patients with metastasis had significantly lower HALP scores compared to those without (p = 0.007). ROC analysis identified a HALP cut-off value of 6.98, yielding a sensitivity of 73% and specificity of 81% (AUC = 0.695; 95% CI: 0.56-0.83; p = 0.013). No significant associations were observed between HALP score and TNM stage or demographic variables. Conclusion: The HALP score is significantly associated with pathological lymph node metastasis in cN0 LAURC patients and may serve as a simple, inexpensive, and clinically applicable biomarker to support preoperative staging. Further prospective studies with survival-based endpoints are warranted to validate its prognostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.